Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

Inclusion criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

• Informed consent obtained before any study-related activities. Study-relatedactivities are any procedures that are carried out as part of the study, includingactivities to determine suitability for the study.

• Male or female, age above or equal to 18 years at the time of signing informedconsent

• Body mass index (BMI) of greater than or equal to 27.0 kg/m^2 with greater than orequal to 2 weight related comorbidities (treated or untreated) according to theJASSO guideline or BMI greater than or equal to 35.0 kg/m^2 with greater than orequal to1 weight related comorbidity (treated or untreated) according to the JASSOguideline. At least one comorbidity should be hypertension, dyslipidaemia or type 2diabetes (T2D)

• History of at least one self-reported unsuccessful dietary effort to lose bodyweight

For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1-4:

• Diagnosed with T2D greater than or equal to 180 days prior to screening

• Treated with either diet and exercise alone or stable treatment (same drug(s), doseand dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OADs) alone or in any combination (metformin, α-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucoseco-transporter 2 inhibitor) or thiazolidinediones)

• HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) as measured by central laboratoryat screening

Exclusion criteria:

Participants without T2D only:

• HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the centrallaboratory at screening

• History of type 1 or type 2 diabetes

• Treatment with glucose-lowering agent(s) within 90 days prior to screening

• Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value ofeGFR brlow 15 ml/min/1.73 m^2 according to Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) creatinine equation as defined by kidney disease improvingglobal outcomes (KDIGO) 2012 classification by the central laboratory at screening

Participants with T2D at screening only:

• Treatment with any medication for the indication of diabetes other than stated inthe inclusion criteria within the past 60 days prior to screening

• Receipt of any other anti-diabetic investigational drug within 90 days prior toscreening for this study, or receipt of any investigational drugs not affectingdiabetes within 30 days prior to screening for this study

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verifiedby a fundus examination performed by an ophthalmologist or another suitablyqualified health care provider within the past 90 days prior to screening or in theperiod between screening and randomisation. Pharmacological pupil-dilation is arequirement unless using a digital fundus photography camera specified fornon-dilated examination.

• Renal impairment measured as eGFR value of below 30 mL/min/1.73 m^2 according to CKDEPI creatinine equation as defined by KDIGO 2012 classification by the centrallaboratory at screening

• In participants treated with SGLT2i, renal impairment measured as eGFR value ofbelow 60 mL/min/1.73 m^2 according to CKD EPI creatinine equation as defined byKDIGO 2012 classification by the central laboratory at screening

The following criteria apply to all participants:

Obesity-related:

• Treatment with any medication indicated for weight management within 90 days priorto screening

• Previous or planned (during the study period) obesity treatment with surgery or aweight loss device. However, the following are allowed: (1) liposuction and/orabdominoplasty, if performed greater than 1 year prior to screening, (2) lapbanding, if the band has been removed greater than 1 year prior to screening, (3)intragastric balloon, if the balloon has been removed greater than 1 year prior toscreening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removedgreater than 1 year prior to screening

• Uncontrolled thyroid disease per investigators discretion

• A self-reported change in body weight greater than 5 kg (11 lbs) within 90 daysbefore screening irrespective of medical records